Lipocine (NASDAQ:LPCN) Earns “Neutral” Rating from HC Wainwright
by Kim Johansen · The Markets DailyLipocine (NASDAQ:LPCN – Get Free Report)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $4.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 80.59% from the stock’s current price.
Several other brokerages have also commented on LPCN. Wall Street Zen raised shares of Lipocine from a “sell” rating to a “hold” rating in a research report on Saturday, July 18th. Weiss Ratings downgraded shares of Lipocine from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Lipocine presently has an average rating of “Reduce” and a consensus target price of $4.00.
Read Our Latest Research Report on LPCN
Lipocine Trading Up 0.2%
Shares of LPCN stock traded up $0.01 during trading hours on Monday, reaching $2.21. 12,420 shares of the company’s stock were exchanged, compared to its average volume of 193,062. Lipocine has a fifty-two week low of $1.81 and a fifty-two week high of $12.37. The stock’s 50 day moving average is $2.19 and its 200-day moving average is $3.12. The company has a market cap of $18.25 million, a price-to-earnings ratio of -1.24 and a beta of 0.47.
Lipocine (NASDAQ:LPCN – Get Free Report) last announced its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.08. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%.The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.21 million. Equities analysts anticipate that Lipocine will post -1.91 EPS for the current year.
Institutional Investors Weigh In On Lipocine
Several hedge funds have recently added to or reduced their stakes in LPCN. Eversept Partners LP acquired a new position in shares of Lipocine in the 1st quarter valued at about $2,357,000. AIGH Capital Management LLC purchased a new stake in shares of Lipocine in the first quarter worth about $1,598,000. Stempoint Capital LP acquired a new stake in Lipocine during the first quarter worth about $1,282,000. Seven Fleet Capital Management LP acquired a new stake in Lipocine during the first quarter worth about $998,000. Finally, Persistent Asset Partners Ltd purchased a new position in Lipocine during the fourth quarter valued at approximately $567,000. 9.11% of the stock is owned by hedge funds and other institutional investors.
About Lipocine
Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.
Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.